Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes.
Abstract
Measurable residual disease (MRD) analysis using circulating tumor DNA (ctDNA) is a non-invasive method of response assessment in large B-cell lymphoma (LBCL), but data supporting its real-world feasibility and performance are needed. We conducted a multicenter, retrospective study of patients with LBCL assessed in real time with a commercially available, immunoglobulin rearrangement-targeted ctDNA-MRD assay (clonoSEQM). Our primary objective was to assess post-treatment MRD after immunochemotherapy or chimeric antigen receptor T-cell (CAR-T) therapy. Median time from sample collection to MRD result was 9 days. Following frontline treatment (N=102), 12-month progression-free survival (PFS) was 15% versus 85% for detectable versus undetectable MRD (HR 14.5, p.